Lisanti Capital Growth LLC Has $561,000 Stock Position in Astera Labs, Inc. $ALAB

Lisanti Capital Growth LLC reduced its position in shares of Astera Labs, Inc. (NASDAQ:ALAB) by 88.2% during the 3rd quarter, HoldingsChannel.com reports. The fund owned 2,865 shares of the company’s stock after selling 21,315 shares during the quarter. Lisanti Capital Growth LLC’s holdings in Astera Labs were worth $561,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently modified their holdings of the company. Bernard Wealth Management Corp. bought a new position in Astera Labs during the second quarter worth about $36,000. Clearstead Trust LLC increased its holdings in shares of Astera Labs by 46,100.0% in the second quarter. Clearstead Trust LLC now owns 462 shares of the company’s stock valued at $42,000 after purchasing an additional 461 shares during the last quarter. Advisors Asset Management Inc. raised its holdings in Astera Labs by 68.6% in the 2nd quarter. Advisors Asset Management Inc. now owns 477 shares of the company’s stock valued at $43,000 after acquiring an additional 194 shares during the period. Manchester Capital Management LLC grew its position in shares of Astera Labs by 141.5% in the second quarter. Manchester Capital Management LLC now owns 483 shares of the company’s stock valued at $44,000 after purchasing an additional 283 shares during the last quarter. Finally, Whittier Trust Co. acquired a new position in shares of Astera Labs in the third quarter valued at about $55,000. Institutional investors own 60.47% of the company’s stock.

Astera Labs Price Performance

ALAB opened at $150.62 on Friday. Astera Labs, Inc. has a fifty-two week low of $47.13 and a fifty-two week high of $262.90. The company’s 50 day moving average price is $163.98 and its two-hundred day moving average price is $171.15. The firm has a market capitalization of $25.44 billion, a price-to-earnings ratio of 135.69, a PEG ratio of 2.19 and a beta of 1.50.

Astera Labs (NASDAQ:ALAB) last issued its quarterly earnings results on Tuesday, November 4th. The company reported $0.49 earnings per share for the quarter, beating the consensus estimate of $0.39 by $0.10. The company had revenue of $230.58 million during the quarter, compared to analysts’ expectations of $206.42 million. Astera Labs had a return on equity of 13.48% and a net margin of 27.50%.The business’s quarterly revenue was up 103.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.23 earnings per share. Astera Labs has set its Q4 2025 guidance at 0.50-0.510 EPS. As a group, equities research analysts predict that Astera Labs, Inc. will post 0.34 EPS for the current year.

Insider Transactions at Astera Labs

In other Astera Labs news, General Counsel Philip Mazzara sold 4,620 shares of Astera Labs stock in a transaction on Monday, November 17th. The shares were sold at an average price of $144.69, for a total value of $668,467.80. Following the completion of the sale, the general counsel directly owned 147,040 shares of the company’s stock, valued at approximately $21,275,217.60. The trade was a 3.05% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Manuel Alba sold 150,000 shares of the stock in a transaction dated Monday, December 1st. The stock was sold at an average price of $166.18, for a total transaction of $24,927,000.00. Following the transaction, the director directly owned 1,574,498 shares in the company, valued at $261,650,077.64. This trade represents a 8.70% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 576,936 shares of company stock valued at $87,409,540. 12.50% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on the stock. Wall Street Zen downgraded shares of Astera Labs from a “buy” rating to a “hold” rating in a report on Tuesday, November 11th. Barclays set a $165.00 price target on Astera Labs in a research report on Thursday, January 15th. Jefferies Financial Group reaffirmed a “buy” rating on shares of Astera Labs in a report on Wednesday, December 3rd. Raymond James Financial assumed coverage on Astera Labs in a research report on Friday, November 21st. They set a “hold” rating for the company. Finally, Zacks Research cut Astera Labs from a “strong-buy” rating to a “hold” rating in a research report on Monday, October 6th. Fifteen equities research analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $190.63.

About Astera Labs

Astera Labs is a fabless semiconductor company that develops connectivity solutions for data center and cloud infrastructure. The firm focuses on addressing signal integrity and link management challenges that arise as server architectures incorporate higher-bandwidth processors and accelerators. Its technology is aimed at improving reliability and performance for high-speed interconnects used in servers, storage systems and compute accelerators.

The company’s product portfolio centers on silicon devices and accompanying firmware and software that enhance and manage high-speed links.